The common heartburn medication Pepcid is in short supply across Canada, and experts say it's a direct result of the recent international recall of Zantac. Zantac, or ranitidine, was recalled in ...

There was no evidence of increased risk for various cancers among patients who used ranitidine compared with those who used famotidine; however, ranitidine users compared with the general ...

Zantac and ranitidine are routinely used by millions of heartburn sufferers. ... The agency tested samples of over-the-counter alternatives such as Pepcid, Tagamet, ...

SEMBACH KASERNE, Germany –The U.S. Food and Drug Administration announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market ...

Over-the-counter versions of ranitidine, including Zantac, are used to treat heartburn. Prescription versions are used to treat stomach ulcers and gastroesophageal reflux disease.

Amidst recalls over the popular heartburn OTC medication Zantac over suspected carcinogens, ... including the likes of Pepcid (famotidine), Tagamet (cimetidine), Nexium (esomeprazole), Prevacid ...

Alternative histamine blockers like famotidine (Pepcid) and cimetidine (Tagamet) have so far not been found to contain NDMA, Dr. Smith said, and neither has Prilosec nor other proton pump inhibitors.

Sanofi has since returned Zantac to store shelves but without ranitidine. It is now made with famotidine, the active ingredient in competitor Pepcid. Originally Published: May 8, 2024 at 12:53 PM CDT ...

Sanofi has since returned Zantac to store shelves, but without ranitidine. It’s now made with famotidine, the active ingredient in competitor Pepcid. Zantac is the third leading antacid sold in ...

All over-the-counter and prescription ranitidine medications-- commonly known by the brand name Zantac -- should be removed from the market “immediately,” the U.S. Food and Drug Administration ...

It’s now made with famotidine, the active ingredient in competitor Pepcid. Zantac is still one of the US’s leading heartburn treatments in a market that generated $14 billion in sales last year.

Proton pump inhibitors, such as Prilosec, Prevacid and Nexium, or so-called H2 blockers, such as Zantac, Pepcid and Tagamet, were linked to a 50 percent increased risk of developing multiple ...